Main publications reporting on transplant cohorts of patients with nonclassical MPN and MDS/MPN
| Author (year) . | MDS/MPN type . | Patient No. . | Tranplant period . | Age, median (range), y . | Donor . | Conditioning . | Stem cell source . | NRM/relapse . | Survival outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Dholaria (2022)8 | CNL | 29 | 2000-2018 | 58 (33-72) | MRD 41% UD 56% MMRD 3% | MAC 48% | PB 93% | NRM 13.8% at 4y CIR 34.5% at 4y | OS 55.2% at 1 y |
| McLornan (2022)9 | CEL/CEL, NOS | 30 | 2000-2018 | 46 (IQR, 40-55) | MRD 30% UD 67% MMRD 3% | MAC 61% | PB 67% | NRM 45% at 3y CIR 20% at 3y | OS 34% at 3 y |
| McLornan (2020)10 | MPN, NOS/MPN-U | 70 | 2000-2015 | NA (22-70) | MRD 39% UD 61% | MAC 44% | PB 91% | NRM 34% at 5y (MAC) CIR 27% at 5y (MAC) | OS 41% at 5 y (MAC) |
| Metzgeroth (2023)11 | MLN-TK | 25 | 2003-2022 | NA | NA | NA | NA | NR | 10/12 alive at 3 y (chronic phase) 7/13 alive at 4.7 y (blast phase) |
| Hernández-Boluda (2022)12 | MLN-TK with FGFR1 rearrangement | 22 | 1997-2018 | 51 (22-67) | MRD 23% UD 68% MMRD9% | MAC 55% | PB 86% | NRM 14% at 5y CIR 23% at 5y | OS 74% at 5 y |
| Tang (2021)13 | MLN-TK with FLT3 rearrangement | 6 | 2005-2020 | 34 (2-43) | NA | NA | NA | NA | 4/6 alive in CR at a median follow-up of 41 mo |
| Onida (2017)14 | MDS/MPN with neutrophilia/aCML | 42 | 1997-2006 | 46 (25-67) | MRD 64% UD 36% | MAC 76% | PB 67% | NRM 24% at 5y CIR 40% at 5y | OS 51% at 5 y |
| Itonaga (2018)15 | MDS/MPN with neutrophilia/aCML | 14 | 2003-2014 | 45 (10-66) | MRD 36% UD 64% | MAC 86% | PB 14% BM 72% CB 14% | NRM 2 relapse/progression 4 | 8/14 alive at last follow-up |
| Kurosawa (2020)16 | MDS/MPN, NOS | 86 | 2001-2017 | 57 (16-71) | MRD 28% UD 72% | MAC 62% | BM/PB 80% CB 20% | NRM 26% at 3y CIR 24% at 3y | OS 49% at 3 y |
| Author (year) . | MDS/MPN type . | Patient No. . | Tranplant period . | Age, median (range), y . | Donor . | Conditioning . | Stem cell source . | NRM/relapse . | Survival outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Dholaria (2022)8 | CNL | 29 | 2000-2018 | 58 (33-72) | MRD 41% UD 56% MMRD 3% | MAC 48% | PB 93% | NRM 13.8% at 4y CIR 34.5% at 4y | OS 55.2% at 1 y |
| McLornan (2022)9 | CEL/CEL, NOS | 30 | 2000-2018 | 46 (IQR, 40-55) | MRD 30% UD 67% MMRD 3% | MAC 61% | PB 67% | NRM 45% at 3y CIR 20% at 3y | OS 34% at 3 y |
| McLornan (2020)10 | MPN, NOS/MPN-U | 70 | 2000-2015 | NA (22-70) | MRD 39% UD 61% | MAC 44% | PB 91% | NRM 34% at 5y (MAC) CIR 27% at 5y (MAC) | OS 41% at 5 y (MAC) |
| Metzgeroth (2023)11 | MLN-TK | 25 | 2003-2022 | NA | NA | NA | NA | NR | 10/12 alive at 3 y (chronic phase) 7/13 alive at 4.7 y (blast phase) |
| Hernández-Boluda (2022)12 | MLN-TK with FGFR1 rearrangement | 22 | 1997-2018 | 51 (22-67) | MRD 23% UD 68% MMRD9% | MAC 55% | PB 86% | NRM 14% at 5y CIR 23% at 5y | OS 74% at 5 y |
| Tang (2021)13 | MLN-TK with FLT3 rearrangement | 6 | 2005-2020 | 34 (2-43) | NA | NA | NA | NA | 4/6 alive in CR at a median follow-up of 41 mo |
| Onida (2017)14 | MDS/MPN with neutrophilia/aCML | 42 | 1997-2006 | 46 (25-67) | MRD 64% UD 36% | MAC 76% | PB 67% | NRM 24% at 5y CIR 40% at 5y | OS 51% at 5 y |
| Itonaga (2018)15 | MDS/MPN with neutrophilia/aCML | 14 | 2003-2014 | 45 (10-66) | MRD 36% UD 64% | MAC 86% | PB 14% BM 72% CB 14% | NRM 2 relapse/progression 4 | 8/14 alive at last follow-up |
| Kurosawa (2020)16 | MDS/MPN, NOS | 86 | 2001-2017 | 57 (16-71) | MRD 28% UD 72% | MAC 62% | BM/PB 80% CB 20% | NRM 26% at 3y CIR 24% at 3y | OS 49% at 3 y |
CB, cord blood; CIR, cumulative incidence of relapse; IQR, interquartile range; MAC, myeloablative conditioning; MMRD, mismatched related donor; MRD, measurable residual disease; NA, not available; PB, peripheral blood; UD, unrelated donor.